Artículos por temáticas

Gene Therapy for Neurological Disease: State of the Art and Opportunities for Next-generation Approaches

Morris G, Schorge S.

Neuroscience. 2022 May 10;490:309-314. doi: 10.1016/j.neuroscience.2022.03.010. Epub 2022 Mar 16.

Amantadine therapy for Parkinson's Disease: In Vivo Confocal Microscopy corneal findings, case report and revision of literature

Cennamo M, Dragotto F, Favuzza E, Morelli A, Mencucci R.

BMC Ophthalmol. 2022 May 10;22(1):211. doi: 10.1186/s12886-022-02410-1.

Clinical outcome measures in dementia with Lewy bodies trials: critique and recommendations

Rodriguez-Porcel F, Wyman-Chick KA, Abdelnour Ruiz C, Toledo JB, Ferreira D, Urwyler P, Weil RS, Kane J, Pilotto A, Rongve A, Boeve B, Taylor JP, McKeith I, Aarsland D, Lewis SJG; Lewy Body Dementias

Transl Neurodegener. 2022 May 2;11(1):24. doi: 10.1186/s40035-022-00299-w.

Adeno-Associated Viruses for Modeling Neurological Diseases in Animals: Achievements and Prospects

Lunev E, Karan A, Egorova T, Bardina M.

Biomedicines. 2022 May 15;10(5):1140. doi: 10.3390/biomedicines10051140.

Comparing adaptive fractal and detrended fluctuation analyses of stride time variability: Tests of equivalence

Hollman JH, Lee WD, Ringquist DC, Taisey C, Ness DK.

Gait Posture. 2022 May;94:9-14. doi: 10.1016/j.gaitpost.2022.02.019. Epub 2022 Feb 17.

Memantine for the patients with mild cognitive impairment in Parkinson's disease: a pharmacological fMRI study

Kawashima S; RCIP-Nagoya Study Group, Matsukawa N.

BMC Neurol. 2022 May 13;22(1):175. doi: 10.1186/s12883-022-02699-x.

Evaluation of an individualized, tablet-based physiotherapy training programme for patients with Parkinson's disease: the ParkProTrain study, a quasi-randomised controlled trial

Wagner L, Hauptmann B, Hoffmann AK, Jochems N, Schmeier B, Schrader A, Kohlmann T, Deck R.

BMC Neurol. 2022 May 14;22(1):176. doi: 10.1186/s12883-022-02647-9.

Baseline Differences in Long-term Survivors and Nonsurvivors of the Colorado/Columbia Fetal Implant Trial

McRae C, Dunk M, Russell D, Ellgring H, Stern Y, Greene P, Fahn S, Henchcliffe C.

J Int Neuropsychol Soc. 2022 May;28(5):452-459. doi: 10.1017/S1355617721000680. Epub 2021 Jun 14.

Exploring the journey of emodin as a potential neuroprotective agent: Novel therapeutic insights with molecular mechanism of action

Mitra S, Anjum J, Muni M, Das R, Rauf A, Islam F, Bin Emran T, Semwal P, Hemeg HA, Alhumaydhi FA, Wilairatana P.

Biomed Pharmacother. 2022 May;149:112877. doi: 10.1016/j.biopha.2022.112877. Epub 2022 Mar 31.

An Exponential Rather Than Multistep Model of Parkinson's Disease Pathogenesis

Foffani G.

Mov Disord. 2022 May;37(5):1105-1106. doi: 10.1002/mds.28997.

The Vagus Nerve Somatosensory-evoked Potential in Neural Disorders: Systematic Review and Illustrative Vignettes

Leon-Ariza JS, Mosquera MA, Siomin V, Fonseca A, Leon-Ariza DS, Gualdron MA, Leon-Sarmiento FE.

Clin EEG Neurosci. 2022 May;53(3):256-263. doi: 10.1177/15500594211001221. Epub 2021 Mar 12.

Milestones in Tremor Research: 10 Years Later

Erro R, Fasano A, Barone P, Bhatia KP.

Mov Disord Clin Pract. 2022 Feb 26;9(4):429-435. doi: 10.1002/mdc3.13418. eCollection 2022 May.

Robot-assisted gait training in patients with Parkinson's disease: Implications for clinical practice. A systematic review

Carmignano SM, Fundaro' C, Bonaiuti D, Calabro' RS, Cassio A, Mazzoli D, Bizzarini E, Campanini I, Cerulli S, Chisari C, Colombo V, Dalise S, Gazzotti V, Mazzoleni D, Mazzucchelli M, Melegari C, Merlo

NeuroRehabilitation. 2022 May 9. doi: 10.3233/NRE-220026. Online ahead of print.

Disordered Decision Making: A Cognitive Framework for Apathy and Impulsivity in Huntington's Disease

Morris LA, O'Callaghan C, Le Heron C.

Mov Disord. 2022 May 2. doi: 10.1002/mds.29013. Online ahead of print.

Clinical evaluation and resting state fMRI analysis of virtual reality based training in Parkinson's disease through a randomized controlled trial

Hajebrahimi F, Velioglu HA, Bayraktaroglu Z, Helvaci Yilmaz N, Hanoglu L.

Sci Rep. 2022 May 16;12(1):8024. doi: 10.1038/s41598-022-12061-3.